Pharmafile Logo
Pharmafocus logo
Advanced Search

opdivo

Showing 15 posts of 107 posts found.

NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer

November 5, 2020
Sales and Marketing BMS, Cancer, NHS, NICE, opdivo

NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …

News
fda2outsideweb

Opdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma

October 6, 2020
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Yervoy, bristol myers squibb, opdivo

Bristol Myers Squibb’s therapy regimen of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) has secured FDA approval for the first-line …

News

Opdivo scores NICE recommendation in two non-small cell lung cancer indications

September 17, 2020
Sales and Marketing NICE, lung cancer, opdivo

NICE has announced its recommendation of Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for the treatment of two non-small cell …

News
4353113087_4d19c3a402_b

Bristol-Myers Squibb demonstrates potential for long-term survival in kidney cancer patients treated with Opdivo plus Yervoy

February 20, 2020
Business Services Cancer, Cancers, Yervoy, opdivo, renacl cell carcinoma, renal cancer

Bristol-Myers Squibb has announced updated results from trialing Opdivo (nivolumab) plus Yervoy (ipilimumab) versus sunitinib in patients with previously untreated …

News
shutterstock_212432119

Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer

February 19, 2020
Research and Development Bristol-Myers Squibb, Five Prime Therapeutics, Pancreatic cancer, cabiralizumab, opdivo, pharma

Five Prime Therapeutics and Bristol-Myers Squibb have confirmed that their randomised Phase 2 trial investigating the efficacy of the former’s …

News
humacao_exterior

BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer

February 3, 2020
Sales and Marketing BMS, Cancer, Europe, Yervoy, lung cancer, opdivo

Bristol-Myers Squibb has confirmed it has withdrawn its application with the European Commission for its combination of Opdivo (nivolumab) and …

News
shutterstock_138095450

Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals

November 19, 2019
Manufacturing and Production, Sales and Marketing Bristol-Myers Squibb, MSD, keytruda, opdivo, pharma

MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 …

News
opdivo_1_1

BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer

October 23, 2019
Research and Development Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …

News
opdivo_1_1

BMS’ Opdivo bests chemotherapy in oesophageal squamous cell carcinoma

October 2, 2019
Research and Development Bristol-Myers Squibb, Cancer, ESMO 2019, opdivo, pharma

Bristol-Myers Squibb took the opportunity at the European Society for Medical Oncology (ESMO) 2019 Annual Congress to present new Phase …

News
opdivo_1_1

EMA’s CHMP recommends new dosing schedule for Opdivo in melanoma

September 25, 2019
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, CHMP, EMA, melanoma, opdivo, pharma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal …

News
opdivo_1_1

BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme

September 5, 2019
Research and Development BMS, glioblastoma multiforme, opdivo, pharma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the …

News
opdivo_1_1

BMS’ blockbuster Opdivo flies high and falls short in non-small cell lung cancer

July 25, 2019
Research and Development Bristol-Myers Squibb, NSCLC, immuntherapy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has pulled back the veil on new data from two analyses of its blockbuster immunotherapy Opdivo (nivolumab) in …

News

BMS Opdivo/Yervoy recommended for untreated kidney cancer via Cancer Drugs Fund

April 5, 2019
Medical Communications, Sales and Marketing CDF, Cancer, Cancer Drugs Fund, Kidney cancer, NICE, UK, Yervoy, opdivo

NICE has revealed it is recommending that Bristol-Myers Squibb’s Opdivo (nivolumab), in combination with Yervoy (ipilimumab), be made available to …

News

Bristol-Myers Squibb withdraws lung cancer combo therapy marketing application

January 25, 2019
Medical Communications BMS, Merck, Yervoy, ctla4, lung cancer, opdivo

Bristol-Myers Squibb has been forced to withdraw a marketing application for its combination of Opdivo and Yervoy for lung cancer. …

News
bmssyracuseny

BMS’ Opdivo+Yervoy combo fails in small cell lung cancer

November 27, 2018
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Cancer, Yervoy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as …

News

Latest content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023